Unlock Breakthroughs with Briya’s Alzheimer’s Dynamic Dataset

Access over 3 Million Data Points, Across Multiple Sites for Comprehensive, Real-World Insights
Group-67210.png
Group-672101.png

Request Your Dataset Now

The Briya Alzheimer’s Disease Dynamic Dataset Coverage includes:

  • Comprehensive patient profiles including age, gender, diagnosis, and disease status
  • Detailed longitudinal data on disease progression and patient follow-ups, spanning back years pre-diagnosis
  • Over 15,000 patients, across 5 sites
  • Extensive biomarker data: Aβ42, pTau217/pTau181, ApoE, Nf-L, GFAP
  • 200,000+ Encounters with Alzheimer’s patients
  • Over 3 million laboratory results with test dates and results
  • Diagnostic imaging data e.g., MRIs, CT scans
  • Unstructured clinical notes including doctors’ notes and treatment details
  • Medication and prescription history linked to disease management
  • Functional studies and tests tracking cognitive decline and progression
  • Data across multiple sites ensuring broad demographic and geographic representation

Leveraging Dynamic Datasets to Unlock Breakthroughs in Azheimer’s Disease

Alzheimer’s affects over 55 million people worldwide, and this number is expected to triple by 2050 as populations age. In the U.S., it is the sixth leading cause of death, with one in three seniors dying from Alzheimer’s or another form of dementia. The disease takes a staggering toll, both physically and financially. Families in the U.S. spend over $300 billion annually on care, while healthcare providers struggle to meet the demands of a growing patient population.

Obtaining relevant data for Alzheimer’s disease research is particularly challenging due to the complex nature of the disease and the need for specific biomarkers that track its progression. Key markers like amyloid-beta accumulation, tau protein tangles, and neurodegeneration must be consistently monitored over long periods to understand the disease’s onset and trajectory. However, acquiring comprehensive, longitudinal data on these biomarkers is difficult, as such data is often fragmented across healthcare systems and research institutions. Additionally, the variability in how these markers present in patients, combined with limited access to standardized, interoperable datasets, hinders the ability to draw meaningful insights. Privacy concerns and regulatory hurdles around patient data further complicate research efforts.

Briya’s dynamic dataset is specifically designed to propel research forward by offering an extensive range of real-world data across crucial clinical and diagnostic parameters, uncovering the full patient journey, spanning back years pre-diagnosis. Including cognitive assessments and neuropsychological tests the dataset also tracks key biomarkers like ApoE, Nf-L, and beta-amyloid, which are critical for understanding Alzheimer’s pathology. Dive deep into biomarkers to uncover early detection opportunities and understand neurodegeneration patterns over time or leverage pre-diagnosis data to identify early risk factors and interventions that could change the course of Alzheimer’s treatment and patient care. With Briya’s Alzheimer’s Disease dynamic dataset, you are equipped to uncover disease mechanisms and develop innovative treatments that make an impact.

Group-67207.png

Benefits of the Dynamic Dataset

Extensive
Data Coverage

Access a high number of cases, even for ultra-rare conditions, enabling more robust and reliable research outcomes.

Comprehensive
Patient Journey

Track detailed patient journeys from diagnosis to treatment outcomes, offering a holistic view of rare disease progression and management.

High-Quality,
De-identified Data

All data is de-identified and standardized, ensuring compliance with privacy regulations while retaining the richness of clinical details.

Group-67184.svg

Seamless
Integration

Our datasets are ready for integration into your research or analytics platforms, making data access straightforward and efficient.

Explore Your
Dynamic Dataset